Loading...
CCXI logo

ChemoCentryx, Inc.NasdaqGS:CCXI Voorraadrapport

Marktkapitalisatie US$3.7b
Prijs aandeel
n/a
Mijn reële waarde
n.v.t.
1Y50.4%
7D0.1%
1D
Portefeuillewaarde
​
Bekijk

ChemoCentryx, Inc.

NasdaqGS:CCXI Voorraadrapport

Marktkapitalisatie: US$3.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx (CCXI) Aandelenoverzicht

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Meer informatie

Beloningen

Verhandeld tegen 62.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 69.08% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Aandeelhouders zijn het afgelopen jaar verwaterd


CCXI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

ChemoCentryx, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor ChemoCentryx
Historische aandelenkoersen
Huidige aandelenkoersUS$51.99
52 Week HoogtepuntUS$52.00
52 Week LaagUS$14.95
Bèta1.23
1 maand verandering0.41%
3 maanden verandering134.51%
1 Jaar Verandering50.39%
3 jaar verandering558.10%
5 jaar verandering642.71%
Verandering sinds IPO372.64%

Recent nieuws en updates

Seeking Alpha • Oct 18

ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company. With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels. NASDAQ said ChemoCentryx's (NASDAQ:CCXI) anticipated last day of trading will be Oct. 19.
Seeking Alpha • Aug 09

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

ChemoCentryx press release (NASDAQ:CCXI): Q2 GAAP EPS of -$0.44 misses by $0.03. Revenue of $11.76M (+553.3% Y/Y) misses by $9.89M. On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022. Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperform

Recent updates

Seeking Alpha • Oct 18

ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company. With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels. NASDAQ said ChemoCentryx's (NASDAQ:CCXI) anticipated last day of trading will be Oct. 19.
Seeking Alpha • Aug 09

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

ChemoCentryx press release (NASDAQ:CCXI): Q2 GAAP EPS of -$0.44 misses by $0.03. Revenue of $11.76M (+553.3% Y/Y) misses by $9.89M. On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022. Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperform
Seeking Alpha • Jun 21

ChemoCentryx: Revisiting The Investment Case

Today, we revisit a biopharma concern called ChemoCentryx for the first time since late in 2021. The company is in the initial rollout of its primary product TAVNEOS, which is approved for one indication and in development for three other diseases. ChemoCentryx has a solid balance sheet and analyst firms are modeling explosive revenue growth ahead for the company. An investment analysis follows in the paragraphs below.
Analyseartikel • Jun 06

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 03

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

CCXI got its first approval last October. Revenue and patient uptake has been good. A few more quarters will be needed to assess the company properly.
Analyseartikel • Feb 11

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyseartikel • Jan 21

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Celebrations may be in order for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Seeking Alpha • Dec 15

Checking In On ChemoCentryx

Today, we put mid-cap biopharma name ChemoCentryx in the spotlight. The company's primary compound was recently approved for the treatment of vasculitis. A full investment analysis is presented in the paragraphs below.
Analyseartikel • Oct 09

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Sep 29

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date was July 2021 but the decision was delayed after ChemoCentryx provided additional data. An FDA Adcom was split over an approval verdict in May. ChemoCentryx stock traded at $68 prior to the Adcom and PDUFA date delay, based on a $1.9bn peak sales potential. Today, shares trade at $20. Avacopan won approval in Japan this week - an encouraging sign - but I suspect the FDA may reject the therapy this time around, and that ChemoCentryx market valuation will fall further as a result - it will be a marginal decision.
Seeking Alpha • Aug 24

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. The good news is that CCXI has not been issued the dreaded complete response letter. The outcome of the PDUFA is dependent on a satisfactory rebuttal to the Adcom questions and comments. Read on for details on the potential regulatory review outcome.
Analyseartikel • Aug 11

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

The latest analyst coverage could presage a bad day for ChemoCentryx, Inc. ( NASDAQ:CCXI ), with the analysts making...
Seeking Alpha • Jul 25

ChemoCentryx: CRL Less Likely

In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date. There are reasons to think the outcome may be positive.
Analyseartikel • Jul 11

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Today we will run through one way of estimating the intrinsic value of ChemoCentryx, Inc. ( NASDAQ:CCXI ) by estimating...
Analyseartikel • Jun 15

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Mar 03

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

We feel now is a pretty good time to analyse ChemoCentryx, Inc.'s ( NASDAQ:CCXI ) business as it appears the company...
Analyseartikel • Feb 04

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Dec 31

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Some ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders may be a little concerned to see that the Independent Director...
Analyseartikel • Dec 23

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Today is shaping up negative for ChemoCentryx, Inc. ( NASDAQ:CCXI ) shareholders, with the analysts delivering a...
Analyseartikel • Dec 13

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
Analyseartikel • Nov 22

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

In this article we are going to estimate the intrinsic value of ChemoCentryx, Inc. (NASDAQ:CCXI) by taking the...

Rendement voor aandeelhouders

CCXIUS BiotechsUS Markt
7D0.1%-1.6%-0.8%
1Y50.4%34.4%27.1%

Rendement versus industrie: CCXI overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 34.4 % opleverde.

Rendement versus markt: CCXI overtrof de US markt, die het afgelopen jaar een rendement opleverde van 27.1 %.

Prijsvolatiliteit

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement31.3%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stabiele aandelenkoers: De aandelenkoers van CCXI is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CCXI is het afgelopen jaar gestegen van 18% naar 31%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1996178n/awww.chemocentryx.com

ChemoCentryx, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ChemoCentryx zich tot de beurswaarde?
CCXI fundamentele statistieken
MarktkapitalisatieUS$3.74b
Inkomsten(TTM)-US$133.09m
Inkomsten(TTM)US$37.28m
100.3x
P/S-verhouding
-28.1x
Koers/Winstverhouding

Is CCXI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CCXI resultatenrekening (TTM)
InkomstenUS$37.28m
Kosten van inkomstenUS$71.86m
Brutowinst-US$34.58m
Overige uitgavenUS$98.51m
Inkomsten-US$133.09m

Laatst gerapporteerde inkomsten

Jun 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.85
Brutomarge-92.76%
Nettowinstmarge-357.01%
Schuld/Eigen Vermogen Verhouding10.5%

Hoe presteerde CCXI op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2022/10/23 21:59
Aandelenkoers aan het einde van de dag2022/10/19 00:00
Inkomsten2022/06/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

ChemoCentryx, Inc. wordt gevolgd door 15 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Madhu KumarB. Riley Securities, Inc.
Harshita PolishettyB. Riley Securities, Inc.
Dae Gon HaBTIG